Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib + obinutuzumab + low-dose bendamustine for high-risk follicular lymphoma (first-line)
ChiCTR2500114118Phase 4Not yet recruiting
- Sponsor
- People's Hospital of Xinjiang Uygur Autonomous Region
- Start
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zanubrutinib, obinutuzumab and bendamustine in follicular lymphoma (FL), sponsored by People's Hospital of Xinjiang Uygur Autonomous Region. Primary endpoint: Complete Response Rate (CRR). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
zanubrutinibobinutuzumabbendamustine
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on ChiCTR2500114118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114118.